Evaluation of serum fibronectin levels and fibronectin gene polymorphism in patients receiving intravesical BCG therapy for non-muscle invasive bladder cancer and its prognostic value

被引:0
|
作者
Nebioglu, Ali [1 ]
Tanriverdi, Rojda [2 ]
Basaranoglu, Mert [3 ]
Saylam, Baris [1 ]
Ulusoy, Ercument [3 ]
Bozlu, Murat [3 ]
Akbay, Erdem [3 ]
Tamer, Lulufer [2 ]
Erdogan, Semra [4 ]
机构
[1] Mersin City Training & Res Hosp, Dept Urol, Korukent Mah 96015 St Mersin Integrated Hlth Campu, TR-33240 Toroslar, Mersin, Turkiye
[2] Mersin Univ, Dept Med Biochem, Fac Med, Mersin, Turkiye
[3] Mersin Univ, Fac Med, Dept Urol, Mersin, Turkiye
[4] Mersin Univ, Fac Med, Dept Biostat & Med Informat, Mersin, Turkiye
来源
BMC UROLOGY | 2024年 / 24卷 / 01期
关键词
BCG; Bladder cancer; Fibronectin; Gene Polymorphism; HEXAMINOLEVULINATE FLUORESCENCE CYSTOSCOPY; WHITE-LIGHT CYSTOSCOPY; TUMOR FIBRONECTIN; HEALTH ECONOMICS; PHASE-III; DIAGNOSIS; CARCINOMA; EXPRESSION;
D O I
10.1186/s12894-024-01592-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background Bladder cancer continues to be a significant health issue, leading to ongoing research into novel biomarkers and treatment strategies. This study aims to evaluate the potential of serum fibronectin levels and fibronectin gene polymorphisms as biomarkers for predicting the recurrence and treatment response in patients with NMIBC undergoing intravesical BCG therapy. Methods Between June 2022 and December 2022, data of 73 patients who applied to the Mersin University Urology Clinic due to NMIBC and were followed and treated in our clinic, receiving intravesical BCG treatment, when necessary, as well as 56 individuals without any malignancy, were prospectively examined. Serum fibronectin levels were measured using the enzyme-linked immunosorbent assay method. PCR testing was applied for the fibronectin gene RS10202709 and RS 35,343,655 gene polymorphisms by using Real-Time PCR. Results The mean serum fibronectin level in the patient group was 76.794 +/- 66.998ng/ml. Simultaneously, it was 50.486 +/- 25.156ng/ml in the control group, and these differences in serum fibronectin levels were statistically significant(p = 0.003). Out of the 73 patients included in the study, recurrence of bladder cancer was observed in 53 of them. They were divided into two groups based on the recurrence times: early recurrence and late recurrence. The mean fibronectin level in the early recurrence group was 102 +/- 86.1 ng/ml, while it was 44.7 +/- 11.8 ng/ml in the late recurrence group. Emphasize the significance of the higher fibronectin levels in the early recurrence group by stating, patients with early recurrence exhibited significantly higher serum fibronectin levels compared to those with late recurrence (p < 0.001), suggesting a potential role for fibronectin as a prognostic biomarker. Conclusions The statistically higher concentrations of serum fibronectin levels in patients with bladder cancer observed in our study are a noteworthy finding. These findings suggest that serum fibronectin levels could serve as a valuable prognostic biomarker for early recurrence in NMIBC patients, although their predictive value for BCG treatment response remains limited.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Association Between Antibiotic Treatment and the Efficacy of Intravesical BCG Therapy in Patients With High-Risk Non-Muscle Invasive Bladder Cancer
    Pak, Sahyun
    Kim, Sun-Young
    Kim, Sung Han
    Joung, Jae Young
    Park, Weon Seo
    Chung, Jinsoo
    Lee, Kang Hyun
    Seo, Ho Kyung
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] The evaluation and outcome of a new intravesical BCG protocol for non-muscle invasive bladder cancer in a tertiary care center In India
    Mukhopadhyay, A.
    Mandal, A. K.
    Singh, S. K.
    Mavuduru, R.
    Modak, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] DETECTION OF CIRCULATING TUMOUR CELLS AS PROGNOSTIC FACTOR IN INTRAVESICAL ADJUVANT THERAPY IN NON-MUSCLE INVASIVE BLADDER CANCER
    De Berardinis, Ettore
    Busetto, Gian Maria
    Antonini, Gabriele
    Di Placido, Mariarosaria
    Nicolazzo, Chiara
    Petracca, Arianna
    Gentile, Vincenzo
    Gazzaniga, Paola
    ANTICANCER RESEARCH, 2010, 30 (04) : 1426 - 1427
  • [44] EVALUATION OF THE UROVYSION™ TEST FOR PREDICTING RECURRENCE AND PROGRESSION IN PATIENTS RECEIVING BCG FOR HIGH GRADE NON-MUSCLE INVASIVE BLADDER CANCER
    Lotan, Yair
    Messing, Edward
    Inman, Brant
    Daneshmand, Siamak
    Kassouf, Wassim
    Canter, Daniel
    Marble, Tony
    Joseph, Ajith
    Boorjian, Stephen A.
    JOURNAL OF UROLOGY, 2018, 199 (04): : E101 - E101
  • [45] Germline DNA copy number polymorphism to predict the efficacy of BCG therapy for non-muscle invasive bladder cancer
    Yamamoto, Yoshiaki
    Ozawa, Sho
    Samoto, Masahiro
    Mori, Junichi
    Inoue, Ryo
    Yano, Seiji
    Hirata, Hiroshi
    Matsumoto, Hiroaki
    Matsuyama, Hideyasu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
    Thomas, Lewis
    Steinberg, Ryan
    Nepple, Kenneth Gerard
    O'Donnell, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [47] Can presence of granuloma act as a marker of response to intravesical BCG in non-muscle invasive bladder cancer?
    Jallad, S.
    Hughes, P.
    Gupta, A.
    Goubet, S.
    Symes, A.
    Larner, T.
    Thomas, P.
    BJU INTERNATIONAL, 2012, 109 : 36 - 36
  • [49] A phase I study of intravesical camrelizumab for BCG failure Non-Muscle Invasive Bladder Cancer (NMIBC)
    Wang, Y.
    Xu, P. H.
    Bian, X. J.
    Lu, X. L.
    Wang, Z.
    Wang, X.
    Yao, X. D.
    Shen, Y. J.
    Ye, D. Y.
    EUROPEAN UROLOGY, 2022, 81 : S251 - S251
  • [50] Intravesical BCG instillation for non-muscle invasive bladder cancer: Prevalence of adverse effects & association with efficacy
    Udovicich, C.
    Nankivell, P.
    Barberi, A.
    Page, D.
    Jenkins, M.
    Goad, J.
    Clarke, A.
    Niall, O.
    Temelcos, C.
    Cleeve, L.
    Wong, L-M.
    BJU INTERNATIONAL, 2015, 115 : 106 - 107